Your browser doesn't support javascript.
loading
Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study.
Mwita, Julius Chacha; Damasceno, Albertino; Chillo, Pilly; Ogah, Okechukwu S; Cohen, Karen; Oyekunle, Anthony; Tefera, Endale; Francis, Joel Msafiri.
Affiliation
  • Mwita JC; Internal Medicine, University of Botswana, Gaborone, South-East District, Botswana mwitajc@ub.ac.bw.
  • Damasceno A; Internal Medicine, Princess Marina Hospital, Gaborone, Botswana.
  • Chillo P; Internal Medicine, University of Eduardo Mondlane Faculty of Medicine, Maputo, Mozambique.
  • Ogah OS; Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, United Republic of Tanzania.
  • Cohen K; Internal Medicine, University of Ibadan College of Medicine, Ibadan, Oyo, Nigeria.
  • Oyekunle A; Clinical Pharmacology, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory 7925 Cape Town, South Africa.
  • Tefera E; Internal Medicine, Bugando Medical Centre, Mwanza, Mwanza, Tanzania, United Republic of Tanzania.
  • Francis JM; Paediatrics and Adolescent Health, University of Botswana, Gaborone, South-East District, Botswana.
BMJ Open ; 12(2): e057166, 2022 Feb 01.
Article in En | MEDLINE | ID: mdl-35105600
ABSTRACT

BACKGROUND:

Given that vitamin K-dependent anticoagulants (VKAs) will continue to be the primary anticoagulant in Africa for a long time, understanding the quality of anticoagulation services in the continent is vital for optimising the intended benefits. Notably, a few small studies have assessed the quality of anticoagulation in sub-Saharan Africa (SSA) countries. This study will describe the current VKA use and anticoagulation control among patients in selected SSA countries. METHODS AND

ANALYSIS:

We plan to review the 2019 anticoagulation data of a cohort of 800 random patients from 19 selected clinics in Botswana, the Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Mozambique, Nigeria, Tanzania and South Africa. We expect at least one participating site to enrol 100 participants in each country. Eligible participants will be those on VKAs for at least 3 months and with at least four international normalised ratio (INR) results. We will document the indications, type and duration of VKA use, sociodemographic factors, coexisting medical conditions, concurrent use of drugs that interact with warfarin and alcohol and tobacco products. The level of anticoagulation control will be determined by calculating the time-in-therapeutic range (TTR) using the Rosendaal and the Percent of INR in TTR methods. A TTR of less than 65% will define a suboptimal anticoagulation control. ETHICS AND DISSEMINATION This study was approved by the Ministry of Health and Wellness Ethics Committee (HPDME13/8/1) in Botswana and local research ethics committees or institutional review boards of all participating sites. As the study collects data from existing records, sites applied for waivers of consent. We will disseminate research findings through peer-reviewed scientific publications.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Vitamin K Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: BMJ Open Year: 2022 Type: Article Affiliation country: Botswana

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Atrial Fibrillation / Vitamin K Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Africa Language: En Journal: BMJ Open Year: 2022 Type: Article Affiliation country: Botswana